NDAINJECTIONINJECTABLE
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
4/8 — Partial
VIBATIV (telavancin) by Theravance Biopharma. Approved for bacterial pneumonia, staphylococcal skin infection. First approved in 2013.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBATIV (telavancin) is a lipoglycopeptide antibiotic administered intravenously to treat serious gram-positive bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, complicated skin and soft tissue infections, and bacteremia. It works by inhibiting bacterial cell wall synthesis, making it effective against resistant pathogens including methicillin-resistant Staphylococcus aureus (MRSA).
$0.782MPart D
PeakVIBATIV is in peak lifecycle but with modest Medicare spending ($782K, 197 claims in 2023), indicating a niche acute-care product with limited team expansion potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Clinical Trials (17)
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Started Jul 2024
20 enrolled
Subarachnoid Hemorrhage, Aneurysmal
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Started Aug 2017
18 enrolled
Cystic Fibrosis
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Started Apr 2016
32 enrolled
Healthy
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Started Jul 2015
8 enrolled
End-Stage Renal DiseaseStage 5 Chronic Kidney Disease
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
Started Dec 2014
22 enrolled
Gram-Positive Bacterial Infections
Worked on VIBATIV at Theravance Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.